Director at Cumberland Pharmaceuticals (CPIX) receives 1,800-share stock grant

Rhea-AI Filing Summary

Cumberland Pharmaceuticals director Martin S. Brown Jr. received a grant of 1,800 shares of Common Stock at $2.80 per share. This award increased his direct holdings to 10,300 shares. The transaction is coded as a grant or award acquisition, indicating compensation rather than an open-market purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Brown Martin S JR

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,800	$2.80	$5K

Holdings After Transaction: Common Stock — 10,300 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brown Martin S JR

(Last) (First) (Middle)

1600 WEST END AVENUE, SUITE 1300

(Street)

NASHVILLE TENNESSEE 37203

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CUMBERLAND PHARMACEUTICALS INC [ CPIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/18/2026		A		1,800	A	$2.8	10,300	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	Martin S. Brown, Jr. by /s/ John Hamm as attorney-in-fact	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Cumberland Pharmaceuticals (CPIX) disclose in this Form 4?

Cumberland Pharmaceuticals disclosed that director Martin S. Brown Jr. received a grant of 1,800 shares of Common Stock at $2.80 per share. The award is coded as a grant or other acquisition, reflecting equity-based compensation rather than an open-market trade.

How many Cumberland Pharmaceuticals (CPIX) shares did the director hold after the grant?

After the 1,800-share grant, director Martin S. Brown Jr. directly held 10,300 shares of Cumberland Pharmaceuticals Common Stock. This updated ownership figure reflects his position following the reported award and helps investors see the scale of his equity stake after the transaction.

Was the Cumberland Pharmaceuticals (CPIX) Form 4 transaction an open-market purchase?

No, the transaction was not an open-market purchase. It is coded as “A” for a grant, award, or other acquisition, meaning the director received 1,800 shares as compensation at a stated value of $2.80 per share rather than buying them on the open market.

Who is the insider involved in this Cumberland Pharmaceuticals (CPIX) Form 4 filing?

The insider is Martin S. Brown Jr., a director of Cumberland Pharmaceuticals. He reported receiving 1,800 shares of Common Stock as a grant, bringing his direct ownership to 10,300 shares. His role as a director means this equity award is part of his compensation structure.

What does the transaction code on the Cumberland Pharmaceuticals (CPIX) Form 4 mean?

The Form 4 uses transaction code “A,” indicating a grant, award, or other acquisition of securities. In this case, director Martin S. Brown Jr. received 1,800 shares of Common Stock at $2.80 per share as a compensation-related equity award, not a market purchase or sale.